An oral selective estrogen receptor modulator approved for treatment of mild to moderate dyspareunia in menopausal women reduced signs and symptoms of atrophy in the vulva, vestibule, urethral meatus and vagina region, according to results of a prospective open-label pilot study
In women with endometriosis, deep dyspareunia is associated with lower sexual quality of life (QoL), according to a study.
Although gabapentin is recommended and commonly prescribed for vulvodynia, its value in such cases is usually associated with complaints that have neuropathic components, such as dynamic allodynia.
The experimental agent TX-004HR effectively improved the vaginal mucosa of postmenopausal women with vulvovaginal atrophy (VVA) and reduced moderate-to-severe dyspareunia and vaginal dryness compared to placebo, according to results of a trial.
Understanding the psychological underpinnings of sexual motivation can be helpful in improving the sexual and relationship well-being of couples affected by vulvodynia, according to recent research.
A small study shows that treatment with CO2 laser induces histological changes in the epithelium and lamina propria that may result in improvement in symptoms associated with vulvovaginal atrophy (VVA).
A newly published pilot study is the first to show that the selective estrogen receptor modulator (SERM) ospemifene effectively normalizes vestibular innervation sensitivity, in addition to confirming that it relieves postmenopausal vestibular signs and symptoms.
Dyspareunia is a common female health problem, according to a large British population probability survey, affecting 7.5% of sexually active women.
Higher levels of distress were linked to increased vaginal sexual symptoms, worry about dyspareunia, dissatisfaction with a relationship, and concerns about body image in a study looking at sexual well-being among cervical cancer survivors.
A lower-dose estradiol vaginal cream than is currently available in the United States was an effective and well-tolerated treatment for dyspareunia in postmenopausal women, according to a recent phase 3, randomized, multicenter, double-blind, placebo-controlled trial.